Eton Pharmaceuticals, Inc. — FY 2018 Form 10-K
Reporting period: Year ended December 31, 2018. The comparison period is April 27, 2017 (inception) through December 31, 2017, so it is a partial-year comparison. The filing was signed March 25, 2019.
Business context
Eton is an early-stage specialty pharmaceutical company developing and commercializing products intended to address unmet needs, primarily through the FDA’s 505(b)(2) pathway; EM-100 uses the 505(j) pathway. It had no FDA-approved products or revenue through year-end and relied on third-party manufacturers, licensors and development partners. Its pipeline includes liquid and injectable products, ophthalmics and DESI conversion candidates.
Financial results and liquidity
| Metric | FY 2018 | 2017 inception period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.627 million | $3.930 million |
| General and administrative expense | $4.694 million | $3.220 million |
| Total operating expenses / operating loss | $10.321 million | $7.150 million |
| Net loss | $12.740 million | $7.156 million |
| Net loss attributable to common stockholders | $37.229 million | $8.639 million |
| Net cash used in operating activities | $8.145 million | $4.718 million |
At December 31, 2018, cash and cash equivalents were $26.735 million, working capital was $25.5 million, total assets were $28.327 million and total liabilities were $2.024 million. The balance sheet reported no debt. The company reported an accumulated deficit of $45.868 million. No operating margin is meaningful because the company had no revenue.
Financing activities provided $21.960 million in 2018, principally from the November IPO, which generated approximately $22.0 million in net proceeds. Cash increased by $13.579 million during the year. Management said existing cash was expected to fund operations and capital expenditures for at least 12 months from issuance of the financial statements, including anticipated progress toward approval and commercial launch of at least one candidate; this depended on spending and development assumptions.
Changes versus the prior period and unusual items
- R&D expense increased by $1.697 million and G&A expense by $1.474 million. Management attributed G&A growth largely to a full year of operations, additional personnel and public-company costs.
- Net loss increased to $12.740 million from $7.156 million, while operating cash use rose to $8.145 million from $4.718 million.
- The 2018 loss included $2.583 million of expense from an increase in the fair value of warrant liability before its reclassification to equity at the IPO. The liability was zero at year-end.
- The $37.229 million loss attributable to common stockholders included $21.747 million of deemed dividends related to the preferred stock’s beneficial conversion feature, plus accrued and other deemed preferred dividends. These items substantially increased common-stockholder loss and per-share loss without representing equivalent operating cash outflow.
- The Series A preferred stock and accrued dividends converted into common stock at the IPO. The IPO sold 4.14 million shares at $6.00 per share.
Pipeline, outlook and risks
- EM-100: A 65-patient bioequivalence trial reported non-inferiority to ZADITOR and superiority to placebo, with no adverse events reported. The company responded to an FDA complete response letter in September 2018. In February 2019, it sold U.S. rights to Bausch for $500,000 upfront, potential commercial milestones of up to $2.5 million and low-double-digit royalties, subject to reductions described in the filing.
- DS-300: Its NDA was submitted in January 2018 and received Fast Track and rolling-review treatment. The filing says the original manufacturing site became unavailable and the product was being transferred to a different FDA-approved site.
- ET-202: Its NDA was submitted in December 2018 and accepted for review; the stated PDUFA target action date was October 2019. Eton licensed U.S. marketing rights in February 2019 and paid $2 million upfront, with a further $750,000 due upon approval.
- DS-200: The NDA was submitted in March 2019, after year-end, as a rolling review. It also received Fast Track designation.
- ET-103: The company had initiated a bridging study and planned to submit an NDA in 2019 if successful. The license included development and sales-related milestones and a 35% net-profit share.
- Management expected to continue increasing G&A as the business grows and public-company costs rise. It planned to build internal commercial capabilities while using third parties for logistics and manufacturing.
- Key risks include regulatory delays or rejection, clinical and development uncertainty, manufacturing-site or supply interruptions, dependence on partners, limited commercialization experience, pricing and reimbursement pressure, competition and potential need for additional capital.
- Several product arrangements involve entities in which the CEO has ownership interests, including DS-100, DS-200 and EM-100-related arrangements. The filing identifies potential conflicts of interest. CT-100’s development costs and timeline were considered inconsistent with the company’s strategy; Eton planned to seek an out-license.
Most important facts for investors to verify
- Current cash runway against actual spending, development costs, milestone obligations and the timing of any further financing need.
- FDA status, review timelines and manufacturing readiness for the filed applications, particularly the DS-300 site transfer and ET-202 review.
- Whether the ET-103 study and other planned development milestones remain on schedule and within expected costs.
- Commercial launch readiness, reimbursement, product demand and the economics of partner profit shares, royalties and milestone payments.
- Terms and governance oversight of related-party agreements, and the effect of potential conflicts on Eton’s economics and obligations.
- Potential dilution from equity awards, warrants or future financing. The audited financial statements received an unqualified opinion; the auditor did not express an opinion on internal-control effectiveness, and management reported disclosure controls were effective.